top of page


FDA approves Teva's Weltruza as first once-monthly subcutaneous olanzapine injection for schizophrenia
Teva has secured FDA approval for Weltruza, the first once-monthly subcutaneous extended-release olanzapine injection for adults with schizophrenia.

nuaxia
Oct 122 min read


FDA approves Teva's DEGEVMA biosimilar to Xgeva across all reference-product indications
The FDA has approved Teva's DEGEVMA as a biosimilar to Xgeva across all reference-product indications, expanding competition in denosumab treatment.

nuaxia
Sep 291 min read
bottom of page